We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The federal government has granted two contracts worth more than $2 billion as part of Operation Warp Speed — $1.6 billion to Novavax to manufacture and develop its COVID-19 vaccine candidate, and $450 million to Regeneron Pharmaceuticals to manufacture and supply its antibody cocktail to treat COVID-19. Read More
Emergent BioSolutions has secured a five-year agreement with Johnson and Johnson to manufacture drug substances for J&J’s COVID-19 vaccine candidate. Read More
The Department of Justice (DOJ) has charged Indian drugmaker Glenmark Pharmaceuticals with allegedly conspiring to increase prices on the cholesterol drug pravastin. Read More
Japanese drugmaker Fujifilm is partnering with India’s Dr. Reddy’s and Dubai-based Global Response Aid (GRA) to manufacture and sell its influenza drug Avigan (favipiravir) for the treatment of COVID-19. Read More
After weeks of waiting, Gilead Sciences announced yesterday that it will charge U.S. insurers $3,120 for a six-vial, five-day course of remdesivir, and a lower price of $2,340 for governments of developed countries, including the U.S. Read More
The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with the Stevanato Group to help solve a serious problem facing vaccine manufacturers as they scale up production — a global shortage of glass vials. Read More
Catalent will also provide clinical supply services from its facilities in Philadelphia to support Moderna’s phase 3 clinical trial of the vaccine. Read More